ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Mainz BioMed NV

Mainz BioMed NV (MYNZ)

0.349
-0.031
(-8.16%)
Closed July 21 4:00PM
0.3489
-0.0001
(-0.03%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.3489
Bid
0.3408
Ask
0.36
Volume
672,756
0.34 Day's Range 0.394
0.315 52 Week Range 4.79
Market Cap
Previous Close
0.38
Open
0.38
Last Trade Time
Financial Volume
$ 242,657
VWAP
0.360692
Average Volume (3m)
641,040
Shares Outstanding
21,165,482
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Mainz BioMed NV

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sector
Testing Laboratories
Industry
Testing Laboratories
Headquarters
Amsterdam, North Holland, Nld
Founded
1970
Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was $0.38. Over the last year, Mainz BioMed NV shares have traded in a share price range of $ 0.315 to $ 4.79.

Mainz BioMed NV currently has 21,165,482 shares outstanding. The market capitalization of Mainz BioMed NV is $8.04 million.

MYNZ Latest News

Micro Cap Bid Up Following FDA Submission Announcement

A medical company based out of Germany is already turning heads during Tuesday’s premarket hours after the company announced the submission of its application to the U.S To read the full...

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia...

Mainz Biomed Reports Results of 2024 Annual General Meeting

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported...

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1211-25.76595744680.470.5020.348808700.43284009CS
4-0.2111-37.69642857140.560.580.31515082970.45235102CS
12-0.5166-59.68804159450.86551.010.3156410400.51737236CS
26-0.8411-70.68067226891.191.220.3153428270.5879974CS
52-4.2211-92.36542669584.574.790.3152604801.14404336CS
156-14.0011-97.56864111514.35300.3151800966.96936817CS
260-14.0011-97.56864111514.35300.3151800966.96936817CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.37M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
204.34k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.12M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
26.52M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

MYNZ Discussion

View Posts
tiger_trader tiger_trader 2 weeks ago
Is there a projected target price on this?
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 weeks ago
MYNZ......................https://stockcharts.com/h-sc/ui?s=MYNZ&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 2 weeks ago
submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non-invasive Next Generation colorectal cancer (CRC) product including the Companyโ€™s novel portfolio of mRNA biomarkers. Subject to the FDAโ€™s review, a Breakthrough Device Designation could significantly accelerate approval.
The regulatory submission follows consistently excellent read-outs of its clinical studies ColoFuture and eAArly Detect, as well as data from a pooled study including both the European and the US arm that were presented at ASCO 2024. On the basis of these studies Mainz Biomed has now defined the final configuration of its Next Generation Test integrating the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm that the Company plans to use in its Next Generation product, and the FDA premarket approval study.

The configuration of the Next Generation Test was tested in a clinical setting. The analysis involved 295 clinical subjects from 21 specialized gastroenterology centers across the United States and highlighted the remarkable efficacy of Mainz Biomed's multimodal screening test. This combination enables precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.

Key Findings

Sensitivity for Colorectal Cancer: 97% (95% confidence interval: 83.3-99.9)
Sensitivity for Advanced Precancerous Lesions: 88% (95% confidence interval: 77.2-94.5)
Specificity: 93% (95% confidence interval: 88.4-98.3)
Guido Baechler, Chief Executive Officer at Mainz Biomed, commented, โ€œOn the back of our extremely positive clinical results in all our recent studies, finalizing the test which will be used in the pivotal ReconAAsense study and approval process has been an elementary milestone for our Company. Our Next Generation Test has shown a significant improvement in sensitivity for advanced adenomas and high-grade dysplasias, combined with high sensitivity and specificity for CRC. Moreover, we believe that our unique decentralized model of working with third party laboratory partners provides better access to underserved communities and our simple collection process will increase the adherence to testing. These benefits support our mission to transform colorectal cancer screening practices and reduce global cancer mortality rates.โ€

The FDAโ€™s Breakthrough Devices Designation is a program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is intended to allow patients and health care providers timely access to medical devices by speeding up development, assessment, and review for premarket approval, 510(k) clearance, and De Novo marketing authorizations. Breakthrough Devices must meet the FDAโ€™s rigorous standards for device safety and effectiveness in order to be authorized for marketing.

Please visit Mainz Biomedโ€™s official website for investors at mainzbiomed.com/investors/ or subscribe to our news alert to keep up to date on our pivotal FDA PMA clinical trial ReconAAsense and further corporate news.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market oppo
๐Ÿ‘๏ธ0
tw0122 tw0122 2 weeks ago
MYNZ .68 + 40%
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 weeks ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
MYNZ new 52+ low
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
MYNZ under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
MYNZ under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
MYNZ new 52 week low
๐Ÿ‘๏ธ0
D60510 D60510 6 months ago
Looking for strong upside for this stock in the March-June 2024 timeliness. Should be aver 3.00 imo
๐Ÿ‘๏ธ0
gail gail 10 months ago
here comes the eod run up after the little dip there.
๐Ÿ‘๏ธ0
gail gail 10 months ago
weeeeeee!
๐Ÿ‘๏ธ0
gail gail 10 months ago
grabbed some this morning at 3.89.
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 1 year ago
Still stable
๐Ÿ‘๏ธ0
BooDog BooDog 1 year ago
That cat bounced. Poped back over $4.
๐Ÿ‘๏ธ0
BooDog BooDog 1 year ago
Watching for the dead cat bounce.
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Provides Full Year 2022 Financial Results

ColoAlert Revenue Increases 130% Year over Year

Year End Cash Balance of $17.1 Million

BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (โ€œMainz Biomedโ€ or the โ€œCompanyโ€), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
This Could Send Mainz Biomed (MYNZ) Soaring Past Wainwrightโ€™s $25 Target https://smallcapexclusive.com/this-could-send-mainz-biomed-mynz-soaring-past-wainwrights-25-target/
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
$MYNZ Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates https://www.benzinga.com/pressreleases/23/03/ab31469781/analysts-model-over-74-upside-for-mainz-biomed-stock-ahead-of-key-1h-2023-updates-mynz
๐Ÿ‘๏ธ0
BEIJING BILL BEIJING BILL 1 year ago
But some... heering fda approval rumbles here.
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (โ€œMainz Biomedโ€ or the โ€œCompanyโ€), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.

Read for release: https://finance.yahoo.com/news/mainz-biomed-announces-partnership-labor-070100006.html
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth

Mainz Biomed's share price weakness presents an opportunity to trade ahead of potential near-term catalysts. Shares dropped on Monday, possibly in sympathy with the Silicon Valley Bankfiasco. However, while MYNZ does list a Berkeley, California connection on its byline, this company is primarily based in Germany. Thus, financial exposure, if any, is more of a distraction than an MYNZ-specific event. Moreover, its significance is outweighed by the planned data releases expected over the next 90 days.

Read full release:
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection

https://finance.yahoo.com/news/mainz-biomed-launches-number-educational-080100640.html
๐Ÿ‘๏ธ0
Mrogers23 Mrogers23 1 year ago
Mainz Biomed has laid the groundwork in 2022 for what could be a transformative 2023. That means from a market cap perspective, its roughly $98 million level could be undervaluing much of the progress made last year. In fact, current valuations could be considered accurate if just historical evidence provided the model's input. But that's not the case. There's plenty of forward-looking considerations contributing to MYNZ's case of deserving a more appropriate and higher valuation. https://www.benzinga.com/pressreleases/23/02/ab31084658/mainz-biomeds-milestones-reached-in-2022-can-be-catalysts-in-1h-2023-heres-why-mynz
๐Ÿ‘๏ธ0
cuggegrosse cuggegrosse 2 years ago
Very,very low float !!!!
👍️ 1
cuggegrosse cuggegrosse 2 years ago
If it ever comes !!!!!
👍️ 1
l2 hunter l2 hunter 2 years ago
MYNZ excellent NEWS OUT >>>>>>>>>> Looks like big time coming. Loaded some shares for 10 X potential for 2023/24 imho...

https://www.globenewswire.com/news-release/2022/12/06/2567955/0/en/Mainz-Biomed-Announces-IRB-Approval-and-Initiation-of-US-Pivotal-FDA-Clinical-Study.html


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AGYP
AITX
AMC
ANY
APCX
APSI
ARIS
AVXL
BIEL
BIG
BLUE
BOMO
BRLL
CAN
CGRA
CLNV
CNNA
COMS
COSM
CPHI
DBGI
DBMM
DRGV
ENZC
ERBB
FOR
GDVM
GOLD
GRPS
GVSI
ICNM
IGEX
IN
INKW
KBLB
KRTL
LLLI
MASN
MJLB
MRNA
MRNJ
MULN
NBLD
NWBO
PLAN
PVSP
REAL
SBEV
SNPW
SNTX
TMNA
TOPS
TPRFF
TSLA
UPIN
WNFT
WSRC
๐Ÿ‘๏ธ0
esi23 esi23 2 years ago
FDA approval in USA will blow this up to 30-40. Market cap 140M

Outstanding 14 M
25% insider owned.

Long term winner
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
โ€œThe Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.โ€
- Guido Baechler, Chief Executive Officer of Mainz Biomed, $MYNZ
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
$MYNZ trading at the high of the day.

ColoAlert - The Companyโ€™s Flagship Product (ColoAlert) Could Become An Inexpensive Alternative In A $3.7 Billion Market? $MYNZ
https://investorbrandmedia.com/mynz-stock-alert/
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
Yes, $MYNZ had an amazing day yesterday... a continuation would be awesome.
๐Ÿ‘๏ธ0
pumpnass pumpnass 2 years ago
Yesterday was a great day, letโ€™s see if we can hold that trend today!!
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
$MYNZ - Mainz Biomed Strengthens Board of Directors...
*Dr. Dreismann, Former Roche Molecular Diagnostics CEO
*Over 35 years of experience in the life sciences and health care industries
*Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive
*Certified Public Accountant with over 30 years of professional experience as a senior financial executive
*Together provide Extensive Experience in Diagnostics and Financial Strategy
https://finance.yahoo.com/news/mainz-biomed-strengthens-board-directors-110000523.html
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
Don't forget about this...$MYNZ - Another Value-Creating Asset, PancAlert...
*Advancing a second portfolio asset
*An early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR)
*Multiplex detection of molecular-genetic biomarkers in stool samples.
*Accurate real-time results
*Can be a first and best-in-class screening for pancreatic cancer
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
$MYNZ coming up on 2x its 10-day average volume as we head into Power Hour... let's rock!
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
Bids increasing, heating up here!

$MYNZ
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
$MYNZ $25.8 million (gross) in new capital, having less than $1 million in long-term debt, and generating revenues from an early cancer detection diagnostics portfolio.
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
Should see $8 in power Hour again... $MYNZ
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
$MYNZ breakout! $8.01 hit and it's consolidating around $7.50... Power Hour should be interesting.
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
7.65 not much on the ask now, $8's coming!

$MYNZ
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
$MYNZ 7.65 up now, something brewing here!
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
WOWZA, really nice volume as $MYNZ now trading nearly 60% over its 10-day average volume with about 3 hours still left in the day... UP almost 2%.
๐Ÿ‘๏ธ0
pumpnass pumpnass 2 years ago
Definitely picking up now
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
$MYNZ now trading nearly 10% over its 10-day average volume in lunchtime... Still holding steady.
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
$MYNZ hot sector here:
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
Nice premarket volume and it's continuing into the open...might break its 10-day average volume within the first hour.
๐Ÿ‘๏ธ0
BlazingStocks BlazingStocks 2 years ago
Wow, great News this morning! $MYNZ trading nearly 70% of its 10-day average volume within the first 30 minutes...and holding steady near yesterday's close.
๐Ÿ‘๏ธ0
budfoxfun budfoxfun 2 years ago
Looks ready for new highs on the week, ask is super thin now!

$MYNZ
๐Ÿ‘๏ธ0
pumpnass pumpnass 2 years ago
Nice pre market volume
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock